Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 3/20 | 0.48 |
| ▸ | PPARA | Q07869 | 2/20 | 0.48 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.45 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | BCL2 | P10415 | 2/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23927937 | 0.85 | HTR2C (0.53) | HDAC1HDAC6 | |
| SCHEMBL23927824 | 0.81 | KMT2A (0.44) | HDAC1HDAC6MCL1 | |
| SCHEMBL30488439 | 0.80 | MEN1 (0.49) | PPARDPPARASRD5A2HDAC1HDAC6 | |
| SCHEMBL30488430 | 0.80 | MEN1 (0.49) | PPARDPPARASRD5A2HDAC1HDAC6 | |
| SCHEMBL25421675 | 0.80 | MEN1 (0.49) | PPARDPPARASRD5A2HDAC1HDAC6 | |
| SCHEMBL25421677 | 0.80 | MEN1 (0.49) | PPARDPPARASRD5A2HDAC1HDAC6 | |
| SCHEMBL23927913 | 0.79 | LTB4R (0.42) | SRD5A2LTB4RLTB4R2BCL2MCL1 | |
| SCHEMBL23927929 | 0.79 | HTR2C (0.51) | HDAC1HDAC6 | |
| SCHEMBL23927907 | 0.79 | HTR2C (0.51) | HDAC1HDAC6 | |
| SCHEMBL25424003 | 0.78 | MEN1 (0.51) | PPARDPPARASRD5A2HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254640-B2 | N-substituted indoles and other heterocycles for treating brain disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-22 | — | — | US | disclosed |
| US-20210332012-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA CORPORATION | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254640-B2 | N-substituted indoles and other heterocycles for treating brain disorders | TPH2, AANAT, HTR2C | PPARD 2143/4885PPARA 3009/4885SRD5A2 997/4885 |
| US-20210332012-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | TPH2, AANAT, HTR2C | PPARD 2143/4885PPARA 3009/4885SRD5A2 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.